Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene
and is constitutively expressed on the surface of immune cells. As a receptor and immune …

Bladder cancer is the 10th most common cancer type in the world. There were more than
573,000 new cases of bladder cancer in 2020. It is the 13th most common cause of cancer …

To explore mechanisms of response to combined PD-1/CTLA-4 immune checkpoint
blockade (ICB) treatment in individual cell types, we generated scRNA-seq using a mouse …

Background In patients affected by high-risk nonmuscle invasive bladder cancer (HR-
NMIBC) progression to muscle invasive status is considered as the main indicator of local …

Introduction: There are various doses, durations, and strains of bacillus Calmette-Guérin
(BCG) intravesical instillation therapy, but optimal treatment has not yet been established …

Background Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with
locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response …

Purpose To develop a novel combination therapy for high-risk nonmuscle-invasive bladder
cancer (NMIBC) after transurethral resection of bladder tumor (TURBT), namely, intra-arterial …

Bladder cancer encapsulates a wide spectrum of disease severities, with non-muscle
invasive bladder cancer (NMIBC) representing an entirely different entity from muscle …

Abstract Development of therapeutic strategies for non-muscle-invasive bladder cancer
(NMIBC) that failed intravesical Bacillus Calmette-Guerin (BCG) therapy remains an urgent …

While the integration of next-generation sequencing and bioinformatics into cancer research
has been immeasurably useful for advancing the field, there are still many gaps in …